IPOs
Filter News
Found 17,237 articles
-
Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market
4/22/2024
Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis” or the “Company”) today announced that it closed its registered direct offering, successfully raising gross proceeds of $59 million through the issuance and sale of 5,000,000 of its ordinary shares, nominal value CHF 0.01 per share (the “Shares”) at a purchase price of $11.75 per Share to investors (the “Financing”).
-
Nanox Files 2023 Annual Report on Form 20-F
4/22/2024
NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023, with the U.S. Securities and Exchange Commission (“SEC”) on April 22, 2024.
-
Cidara Therapeutics Announces Reverse Stock Split
4/22/2024
Cidara Therapeutics, Inc. today announced that the Company effected a reverse stock split of its issued and outstanding common stock, at a ratio of 1-for-20.
-
INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offering
4/22/2024
INmune Bio, Inc. today announced today that it has entered into definitive agreements for the sale and purchase of 571,592 shares of its common stock with above market warrant exercise price.
-
TScan Therapeutics Announces Closing of Upsized Public Offering
4/19/2024
TScan Therapeutics, Inc. today announced the closing of an underwritten public offering of 2,472,581 shares of its voting common stock at a public offering price of $7.1300 per share.
-
PharmAla Closes Private Placement and Concurrent Debt Settlement
4/19/2024
PharmAla Biotech Holdings Inc. is pleased to announce that, further to its press release dated April 10, 2024 (the “ April 10 Release ”), the Company has closed its previously announced non-brokered private placement offering.
-
Concord Medical Files 2023 Annual Report on Form 20-F
4/19/2024
Concord Medical Services Holdings Limited today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 (the "Annual Report") with the U.S. Securities and Exchange Commission.
-
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - April 18, 2024
4/18/2024
Schrödinger, Inc. today reported that on April 15, 2024, the company granted (i) non-statutory stock options to purchase 3,600 shares of the company’s common stock to three newly hired employees and (ii) restricted stock units (RSUs) with respect to 9,613 shares of the company’s common stock to nine newly hired employees.
-
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
4/18/2024
Benitec Biopharma Inc. today announced a $40.0 million private investment in public equity (PIPE) financing from the sale of 5,749,152 shares of its common stock at a price per share.
-
Windtree Therapeutics Announces Reverse Stock Split - April 18, 2024
4/18/2024
Windtree Therapeutics, Inc. today announced that the Company’s Board of Directors has approved a 1-for-18 reverse stock split of its issued and outstanding common stock, par value of $0.001 per share (the “Reverse Stock Split”).
-
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
4/17/2024
Allarity Therapeutics, Inc today announced that it had been granted an extension until May 14, 2024, to regain compliance with Nasdaq Listing Rule 5550(b)(1).
-
Allurion Closes $48 Million Convertible Senior Secured Note Financing with RTW Investments
4/17/2024
Allurion Technologies, Inc. today announced the closing of a $48 million convertible senior secured note financing with certain entities managed by RTW Investments, LP (“RTW”).
-
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds
4/17/2024
Longeveron Inc. today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares.
-
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering
4/16/2024
Calidi Biotherapeutics, Inc. today announced the pricing of its “reasonable best efforts” public offering of 15,197,500 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying Series A Common Warrants.
-
Sunshine Biopharma Announces Reverse Stock Split
4/12/2024
Sunshine Biopharma, Inc. announced today a one for one hundred reverse split of its common stock, effective at market open on April 17, 2024.
-
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/11/2024
bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of 102,700 restricted stock units (“RSUs”) to twelve newly hired employees with a grant date of April 9, 2024 (the “Inducement Grants”).
-
Leap Therapeutics Announces $40 Million Private Placement
4/11/2024
Leap Therapeutics, Inc. today announced it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 12,660,993 shares of its common stock ("Common Stock") at a price of $2.82 per share and pre-funded warrants to purchase 1,523,404 shares of Common Stock at a price of $2.819 per share of Common Stock.
-
IMUNON Reports Compliance with Nasdaq Listing Requirements
4/11/2024
IMUNON, Inc. today announced that on April 10, 2024, it received written notice from the staff of The NASDAQ Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for continued listing on The Nasdaq Capital Market.
-
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
4/11/2024
Aptevo Therapeutics Inc. today announced the pricing of a public offering of (i) 3,400,000 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 6,800,000 shares of its common stock.
-
Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market
4/11/2024
Oculis Holding AG (Nasdaq Global Market: OCS) (“Oculis” or the “Company”), today announced that on April 11, 2024 it completed a financing of approximately $59 million, consisting of the issuance of 5,000,000 of its ordinary shares, nominal value CHF 0.01 per share (the “Shares”) at a purchase price of $11.75 per Share.